Meningeal immunity and “Interstitial” therapy: a new paradigm for immunotherapy in glioblastoma
-
By
-
Hongan Fei
-
Xichao Wen
-
Wensong Wu
-
HaiPeng Liu
-
Haipeng Xie
-
Yan Wang
-
Kebin Zheng
-
Zhaomu Zeng
-
Zetong Bai
-
June 15, 2026
-
Clinical Scorecard: Meningeal Immune Response and 'Interstitial' Treatment: A Novel Approach to Immunotherapy for Glioblastoma
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Meningeal immune system, resident border-associated macrophages (rBAMs), interstitial immunotherapy, dural lymphatic system |
| Target Population | |
| Care Setting | |
Key Highlights
- Meningeal vascular blockage may enhance T cell activation and anti-tumor immunity.
Guideline-Based Recommendations
Diagnosis
Management
- Explore interstitial immunotherapy targeting the meningeal immune system.
- Consider immune checkpoint inhibitors and CAR T cell therapies in GBM management.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Meningeal vascular blockage may promote T cell activation and enhance anti-tumor immunity, suggesting a novel therapeutic approach.
Clinical Best Practices
- Utilize insights from the meningeal immune system to inform GBM treatment strategies.
- Consider the role of rBAMs in shaping the immune response in GBM.
- Implement monitoring strategies for rBAM abundance as a potential biomarker.
Related Resources & Content
